Stanford-LPCH
Vaccine Program

Clinical Trials

Completed Studies

Current Studies

The following are ongoing vaccine clinical trials conducted by the Stanford-LPCH Vaccine Program. For more information about clinical trials and a nationwide database of clinical trials, please go to ClinicalTrials.gov.

For general information about participant rights, contact 1-866-680-2906

Our clinic location is at 800 Welch Road, Palo Alto, CA 94304. General phone # (650) 498-7284.


 

When you click "JOIN OUR MAILING LIST " icon, please join our mailing list so we can contact you.

Mailing List

Links to studies:

Seasonal Flu Vaccine Studies

We have several seasonal flu vaccine studies each year in the fall.
Find your age below to be directed to the appropriate trials:



Enrolling Now

65-100 years old
Shingles Vaccine Study (Age-Related Immune Response to Varicella Zoster Virus



11-13 months old (Enrollment Closed
Bangladesh Study

1-2 years old (Enrollment Closed)
2013 Seasonal Flu Vaccine Study

1-3 years old (Enrollment Closed)
Immune Responses to Influenza-like Illness

1-8 years old
(Enrollment Closed)
Seasonal Flu Vaccine Study for Twins

8-34 years old
Seasonal Flu Vaccine Study

18 and older (Enrollment Closed)
Immune Responses to Influenza-like Illness

18-30 years old (Enrollment Closed)
2013 Seasonal Flu Vaccine Study (Enrollment Closed)
Adult Seasonal Flu Vaccine Study - Longitudinal Study

60-100 years old
Adult Seasonal Flu Vaccine Study - Longitudinal Study (Closed to new enrollments)


2012-2013 Experimental Seasonal Influenza DNA Vaccine Study (Enrollment Closed)

NIH-Sponsored Malaria Vaccine Trial
(Enrollment Closed)







Bangladesh

Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh

(Enrollment Closed)


Oral vaccines are given to children around the world to prevent diseases that have serious, long-term or fatal consequences. Two such vaccines, the oral polio vaccine and oral rotavirus vaccine, aim to prevent children from getting sick with paralytic polio or rotavirus diarrhea: two potentially devastating illnesses.  However, these vaccines are generally not as effective at preventing disease in children living in developing countries, like Bangladesh, as they are in developed countries. The Stanford-LPCH Vaccine Program is seeking healthy infants to take part in a research study to look at immune response differences between healthy children living in the United States compared with children from India and Bangladesh. This will possibly lead to the development of more effective vaccines.
To be eligible your child must be:

Your child will not receive any vaccinations or medications by taking part in this study
You will receive $ 30.00 compensation and a parking voucher for your participation.
ELIGIBILITY:
To review the complete list of eligibility requirements and to learn more about the visit schedule for this study, please click this link: ** Eligibility Criteria and Visit Schedule **
For further information or to volunteer:

Please contact the Stanford-LPCH Vaccine Program at (650) 498-7284 or email us at Vaccines_Program@stanford.edu




Immune Responses to Influenza-like Illness (Enrollment Closed)

ILI_virusSummary:  Stanford LPCH Vaccine program is seeking children age 1-3 years old or  adults, age 18 years or older, who are currently experiencing flu-like symptoms to participate in a flu research study. The research will be conducted at Stanford University by Dr. Cornelia L. Dekker, M.D., Professor of Pediatrics at Stanford (Stanford-LPCH Vaccine Program), Mark M. Davis, Ph.D., Professor of Microbiology and Immunology and Dr. Harry B. Greenberg, M.D., Senior Associate Dean for Research.  The goal is to investigate how the adult immune system responds to natural infection by this season’s influenza viruses.

Study Participation, to qualify you must have:

If eligible, you will receive:

ELIGIBILITY:
To review the complete list of eligibility requirements and to learn more about the visit schedule for this study, please click this link: ** Eligibility Criteria and Visit Schedule **

For further information or to volunteer:

Please contact the Stanford-LPCH Vaccine Program at (650) 498-7284 or email us at Vaccines_Program@stanford.edu




B-Cell2013 Seasonal Flu Vaccine Study (B cell) (Enrollment Closed)

B cell Immunity to Influenza and Measuring the Immunome: Genomic Approaches to B cell Repertoire

 

SUMMARY The Stanford-LPCH Vaccine Program is seeking healthy children, and young adults to take part in an influenza (commonly known as "the flu") vaccine study.  In this study, we will be looking at the B cell immune response differences between age groups to the flu vaccine. We would like to compare the B-cell response to flu vaccine in vaccine-naïve young children and in young adults who did not receive a seasonal influenza vaccination in 2012-2013.
 The vaccine used in the study is licensed by the FDA and is not experimental.  It’s the same seasonal flu vaccine that will be given to the public during the fall flu season.   

The research will be conducted at Stanford University by Dr. Cornelia L. Dekker, M.D., Professor of Pediatrics at Stanford (Stanford-LPCH Vaccine Program) and Mark M. Davis, Ph.D. (Institute of Immunity, Transplantation and Infection).

To be eligible you or your child should be:

If eligible, you will receive:

ELIGIBILITY: To review the complete list of eligibility requirements and to learn more about the visit schedule, please click this link: ** Eligibility Criteria and Visit Schedule**

For further information or to volunteer for other research studies:





SHIMR
Seasonal Flu Vaccine Study: For 8-34 years old
Vaccination and infection: indicators of immunological health and responsiveness; Project 1: Plasmablast trafficking and antibody response in influenza vaccination. SLVP021 - 2014


The Stanford-LPCH Vaccine Program is seeking healthy children and young adults age 8-34 year olds to take part in an influenza (commonly known as "the flu") vaccine study. Participants must have either participated in this study previously (2012 and/or 2013) or a new participant who has not received flu shot in last 3 years. Past participants will receive the same type of vaccine they received with their prior study vaccine assignment - either the intramuscular (standard flu shot into the arm muscle) or the intradermal (into the skin of the arm) vaccine.  New participants will receive intramuscular (standard flu shot into the arm muscle) vaccine.  All vaccines are licensed by the FDA and are not experimental. These are the same seasonal flu vaccines that will be used for the public during the fall flu season.

The study will compare the B-cell immune responses by analyzing the trafficking receptor expression on vaccine-induced plasmablasts, their immunoglobulin gene-repertoire, as well as functions of PPAb derived from plasmablast subsets based on trafficking receptor phenotypes.

The research will be conducted at Stanford University by Dr. Cornelia L. Dekker, M.D., Professor of Pediatrics at Stanford (Stanford-LPCH Vaccine Program) and Mark Davis, Ph.D. (Institute of Immunity Transplantation and Infection)

To be eligible, must have either previously participated in our flu vaccine studies in 2012 and/or 2013 or you are new participant who has not received a flu shot in last 3 years. In addition you should be:

If eligible, you will receive:

ELIGIBILITY:
To review the complete list of eligibility requirements and to learn more about the visit schedule for this study, please click this link: ** Eligibility Criteria and Visit Schedule **

For further information or to volunteer:
Please contact the Stanford-LPCH Vaccine Program at (650) 498-7284 or email us at Vaccines_Program@stanford.edu






T-cellSeasonal Flu Vaccine Study for Twins (T-cell Responses Y5-2013-2014)(Enrollment Closed)
T-cell and General Immune Responses to Influenza, Single-cell Phospho-protein Signaling Analysis of the Response to Influenza Vaccination and Measuring the Immunome: Genomic Approaches to B-cell Repertoire


SUMMARY The Stanford-LPCH Vaccine Program is seeking healthy young twins, 1-8 years old, to take part in an influenza (commonly known as "the flu") vaccine study.  This study will investigate markers and mechanisms and define general predictors for immunological health. This goal is analogous to what has been achieved in cardiovascular medicine where the levels of different forms of cholesterol have provided useful benchmarks for cardiovascular health

In this context, immunization with approved flu vaccines represents a safe and accessible opportunity to gauge the immune response in a particular individual as a function of age and genetics and then to try to find predictive biomarkers. The vaccines used are licensed by the FDA and are not experimental.  They are the same seasonal flu vaccine that will be used for the public during the fall flu season.  The research will be conducted at Stanford University by Dr. Cornelia L. Dekker, M.D., Professor of Pediatrics at Stanford (Stanford-LPCH Vaccine Program) and Mark Davis, Ph.D. (Institute of Immunity Transplantation and Infection)
 

To qualify you should be:

If eligible, the child will receive:

ELIGIBILITY:
To review the complete list of eligibility requirements and to learn more about the visit schedule for this study, please click this link: ** Eligibility Criteria and Visit Schedule **
For further information or to volunteer:

Please contact the Stanford-LPCH Vaccine Program at (650) 498-7284 or email us at Vaccines_Program@stanford.edu

If you are a twin, and would like to join the Twin Research Registry at SRI International (not affiliated with Stanford University), call 1-800-SRI-TWIN (1-800-774-8946).  You may be eligible to participate in other research studies that could help scientists advance new treatments for diseases and explain the roles of genetics and the environment in health and behavior.




Varicella
Varicella Zoster Virus (VZV)

Study of Age-Related Immune Responses to VZV
T Cell Responses to Varicella Zoster Virus After Vaccination and Viral Escape





Summary:  The Stanford-LPCH Vaccine Program is seeking healthy adults to take part in a study of the immune system of individuals who have had chickenpox in the past in order to learn more about  the influence of age and inherited factors on VZV-specific T cell response in naturally-acquired VZV immunity and the response to VZV vaccination. This knowledge may lead to an improvement in vaccination strategies and identification of ways to improve vaccine responses in older individuals. 

Study Participation
The varicella zoster virus (VZV) causes chickenpox (also known as varicella) the first time a person is infected.  However, decades after a person has had chickenpox, the virus can reactivate in the body to cause a condition called shingles (also known as zoster).  We will measure the immune responses to the naturally-acquired varicella zoster virus in order to learn more about age-related differences in immune function.  We will also study the vaccine-induced responses in volunteers 50 years of age and older.  The trial is sponsored by National Institutes of Health.  There are two parts to the study:  one for volunteers between the ages of 40-49 years and another for volunteers 50 years of age and older.

Participation for volunteers 40-49 years of age will include one clinic visit with one blood draw. (Volunteers in this age group will not receive the shingles vaccine)

Participation for volunteers 50 years of age and older will include five clinic visits with five blood draws.  This age group will also receive a free shingles vaccination.  The vaccine is licensed by the FDA and is not experimental.  The vaccine is recommended for individuals 50 years of age and older and has been shown to help prevent shingles and to reduce the severity and duration of those who develop shingles. 

The research will be conducted at Stanford University School of Medicine by Jorg Goronzy, M.D., Ph.D., Professor of Medicine and Dr. Cornelia L. Dekker, M.D., Professor of Pediatrics (Stanford-LPCH Vaccine Program).   

Volunteers will receive reimbursement for each clinic visit completed.  There will be no costs for participating in the study and parking vouchers will be provided. 

Eligibility:

Eligibility:
To review the complete list of eligibility requirements and to learn more about the visit schedule for this study, please click this link: ** Eligibility Criteria and Visit Schedule **
FOR MORE INFORMATION OR TO VOLUNTEER:
Please contact the Stanford-LPCH Vaccine Program at (650) 498-7284 or email us at Vaccines_Program@stanford.edu





DNA_Vaccine 2012-2013 Experimental Seasonal Influenza DNA Vaccine Study (Enrollment Closed)
                 
An Open-Label, Randomized Phase 1b Study of the Safety and Immunogenicity of Investigational Seasonal Influenza DNA Vaccine (HA DNA), Followed by Trivalent Inactivated VAccine (TIV) Administered Intradermally (ID) or Intramuscularly (IM) in Healthy Adults Ages 18-70 Years (VRC703)

SUMMARY The Stanford-LPCH Vaccine Program is seeking healthy adults to take part in an experimental universal flu vaccine study.  The purpose of this trial is to study the the safety and effectiveness of three different  seasonal flu vaccines.  The other main purpose is to see which vaccination schedules result in the best immune responses.  The research will be conducted at Stanford University by Cornelia L. Dekker, M.D., Professor of Pediatrics.  This trial is sponsored by the National Institutes of Health (NIH). Three different types of flu vaccines are being studied. Two are regular seasonal flu vaccine that is approved by the Food and Drug Administration (FDA) for use in the influenza season. The other vaccine is experimental and is not approved by the FDA.  

You will be randomly assigned to one of 6 groups.

Groups 1 and 2: [Enrollment for Groups 1 & 2 is closed] Volunteerswill be assigned to receive a DNA vaccine in September 2012 and then be given a booster with a licensed seasonal flu vaccine in November/December 2012.
Groups 3-6: Volunteers will be assigned to receive any combination of DNA vaccine and/or a licensed seasonal flu vaccine in November/December 2012 and then be given a booster of a licensed seasonal flu vaccine in approximately August/September 2013.

To qualify you should be:

If eligible, you will receive:

ELIGIBILITY:
To review the complete list of eligibility requirements and to learn more about the visit schedule for this study, please click this link: ** Eligibility Criteria and Visit Schedule **  To review a copy of the informed consent, please click this link: ** Informed Consent**

For further information or to volunteer:
Please contact the Stanford-LPCH Vaccine Program at (650) 498-7284
or email us at Vaccines_Program@stanford.edu or Join Our Mailing List (see Link on left-side of web page).






Adult Seasonal Flu Vaccine Study - Longitudinal Study



Flu

Immune Senescence in the Elderly: Comparison of Immune Reponses to Influenza Vaccine in Adults of Different Age Groups




SUMMARY The Stanford-LPCH Vaccine Program is seeking healthy adults to take part in an influenza vaccine study (commonly known as "the flu").  We hope to discover new biological markers that are associated with the age-related immune response to the seasonal flu vaccine. 
The flu vaccine used in this study is licensed by the FDA and is not experimental.  Because we are interested in understanding how the immune response changes over time in the same individual, volunteers will be asked to participate annually through the end of the funding period.

The research will be conducted at Stanford University by Cornelia L. Dekker, M.D., Professor of Pediatrics, and by Mark M. Davis, Ph.D., Professor of Microbiology and Immunology.  The trial is sponsored by the National Institutes of Health, and the Bill and Melinda Gates Foundation.

To be eligible you should be:
Generally Healthy                                                                                            
18-30 or 60-100 years old at time of enrollment
Able to attend 3 clinic visits at Stanford
Able to provide 3 blood samples

If eligible, you will receive:
Current licensed seasonal flu vaccine
$30 per clinic visit attended
Parking vouchers

ELIGIBILITY:
The study is open to volunteers who have been previously enrolled in this study and to new volunteers. To view the eligibility requirements and visit schedule, please click this link: ** Eligibility Criteria and Visit Schedule  **

For further information or to volunteer:
Please contact the Stanford-LPCH Vaccine Program at (650) 498-7284
or email us at Vaccines_Program@stanford.edu





========================================================================

Malaria Map


NIH-Sponsored Malaria Vaccine Trial (Enrollment Closed)

A Phase I, Randomized, Controlled, Dosage-Escalation Trial to Evaluate the Immungenicity, Safety, Reactogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Healthy Adults 18 to 45 Years of Age. (DMID 05-0050)

Thank you for visiting the Stanford-LPCH Vaccine Program website to learn more about the NIH-sponsored Malaria Vaccine Clinical Trial.

SUMMARY: Malaria is caused by the Plasmodium parasite and is transmitted from person-to-person through the bite of a female Anopheles mosquito. The disease currently represents one of the most prevalent infections in tropical and subtropical areas causing severe illness in 300 to 500 million individuals worldwide and causing up to three million deaths every year. Most of these deaths occur among children and pregnant women in the developing world, especially in sub-Saharan Africa. Although most people affected with malaria are from the developing world, the disease also affects travelers.



 



 

Stanford Medicine Resources:

Footer Links: